Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADL5747 for Postherpetic Neuralgia
NCT01058642Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Jan 2010
- Primary completion
- Dec 2010
- Countries
- 1
01
Overview
A Phase 2 trial of ADL-5747 in postherpetic neuralgia (PHN), sponsored by Merck & Co.. Started Jan 2010; status: terminated.
02
Drugs
ADL-5747
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on NCT01058642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01058642.